Biomarkers in Twin Pregnancies to Predict Preeclampsia and Preeclampsia-Related Complications

Conditions: Toxemia of Pregnancy
10026908

Registration Number: NL-OMON49445

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 74

Inclusion Criteria

Healthy Controls:
- Women with a twin pregnancy
- Age * 18 years
- No pre-existing hypertension, proteinuria, renal or other autoimmune disease
- No suspicion of PE
- No suspicion of fetal growth restriction
- Gestational age *20 weeks and <37 weeks.

Women with confirmed PE:
- Women with a twin pregnancy
- Age * 18 years
- Confirmed PE
- Alive fetus without fetal distress requiring immediate delivery
- Gestational age * 20 weeks and <37 weeks.

Exclusion Criteria

- The presence of fetal death at time of inclusion.
- Pregnancy with a fetus affected by major congenital birth defects and/or
chromosomal abnormalities
- Unable to provide written informed consent.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. PAPP-A2 and inhibin A levels in twin PE pregnancies versus twin healthy<br /><br>pregnancies.<br /><br>2. PAPP-A2 and inhibin A levels in twin (healthy) pregnancies in comparison<br /><br>to singleton (healthy) pregnancies.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Biomarker level course across gestational age (PAPP-A2, inhibin A,<br /><br>sFlt-1 and PlGF) in twin pregnancies in women with healthy vs. confirmed PE.<br /><br>- Correlation between PAPP-A2, inhibin A, sFlt-1 en PlGF levels in twin<br /><br>pregnancies.</p><br>